A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

Part of paid clinical trials in Los Angeles, California.

Sponsor
Verastem, Inc.
Study ID
NCT07659795
Phase
PHASE2
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • VS-7375 — DRUG
    Taken by mouth
  • cetuximab — DRUG
    Intravenous infusion
  • panitumumab — DRUG
    Intravenous infusion
  • Cetuximab + mFOLFOX6 — DRUG
    Intravenous infusion

Study Details

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer

Key Dates

Start date
Jul 31, 2026
Status verified
Jul 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: VS-7375 Monotherapy or Preferred Combination in 2L+ CRC
    Participants randomized to a treatment in 2:1 ratio
  • Experimental: VS-7375 with chosen regimen in 2L+ CRC
  • Experimental: VS-7375 + cetuximab and mFOLFOX in 1L CRC

Primary Outcome Measure

Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only [ Time Frame: 6 months ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
START Los AngelesLos AngelesCalifornia90025
START Hope Team
424-465-1820
Navid Hafez, M.D., MPH (PRINCIPAL_INVESTIGATOR)
START MidwestGrand RapidsMichigan49546
START Hope Team
616-954-5554
Sreenivasa R Chandana, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)
START New JerseyEast BrunswickNew Jersey08816
START Hope Team
732-426-4750
Bruno S Fang, M.D. (PRINCIPAL_INVESTIGATOR)
START Dallas Fort WorthFort WorthTexas76104
START Hope Team
682-350-3010
Salwan Al Mutar, M.D., M.Sc. (PRINCIPAL_INVESTIGATOR)
START Mountain RegionWest Valley CityUtah84119
START Hope Team
801-907-4750
José M Pacheco, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By condition

Related Studies